Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Secukinumab versus adalimumab monotherapy in active psoriatic arthritis
MOH_2017-06-05_000264Phase 3Completed
- Sponsor
- Novartis
- Start
- May 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in psoriatic arthritis (PsA) comparing Secukinumab monotherapy with Adalimumab monotherapy (2 arms). Primary endpoint: Efficacy at week 52. Started May 2017; status: completed.
02
Drugs
secukinumabadalimumab
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on MOH_2017-06-05_000264.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-06-05_000264.